In the Claims:

Please cancel claims 1-11, 14, 17-19 and 22-35 without prejudice thereto. Please amend the claims as follows:

Claims 1 - 11 (canceled)

12. (currently amended) A method ~~for regulating~~ of increasing I-BABP expression in a mammal ~~which comprises activating or inhibiting the Farnasoid X Receptor~~ comprising administering an effective amount of a non-steroidal Farnesoid X Receptor agonist to said mammal.

13. (currently amended) The method of claim 12, ~~which comprises binding an activating amount of chenodeoxycholic acid to the Farnesoid X Receptor~~ where said Farnesoid X Receptor agonist is GW4064.

14. (canceled)

15. (currently amended) A method of ~~regulating the bile transport system~~ increasing bile acid transport from the intestinal lumen across the intestinal membrane in a mammal which comprises ~~activating the Farnesoid X Receptor with a binding ligand~~ administering an effective amount of a non-steroidal Farnesoid X Receptor agonist to said mammal.

16. (currently amended) The method of claim 15, wherein said FXR agonist is GW4064 ~~the binding ligand is GW4064, chenodeoxycholic acid, lithocholic acid, deoxycholic acid, or a glycine or taurine conjugated conjugate derivative thereof~~.

17-19 (cancelled)

20. (currently amended) A method of lowering serum triglycerides ~~treating~~ in a mammal ~~a disease which is affected by cholesterol, triglyceride, or bile acid levels~~

comprising administering to a mammal in need of such treatment ~~a therapeutically effective~~ an effective serum triglyceride lowering amount of a non-steroidal agonist ~~ligand~~ for Farnesoid X Receptor.

21. (currently amended) A method of treating ~~atherosclerosis, gallstone disease, lipid disorders,~~ obesity ~~or a cardiovascular disorder~~ in a mammal in need of such treatment, comprising administration of a therapeutically effective amount of a ~~compound which was identified by the method of Claim 4~~ non-steroidal FXR agonist.

22-35 (canceled)